Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma-Reference-Cited by-同舟云学术

Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma

Published:2022-05 Issue:2 Volume:109 Page:2S31-2S38
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:en
Short-container-title:Bulletin du Cancer

Author:

Flippot Ronan,Gorgeu Violaine,Pujalte Marc,Colomba Emeline,Alves Carolina,Cerbone Luigi,Carril Lucia,Derosa Lisa,Escudier Bernard,Albigès Laurence

Funder

Ipsen

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference48 articles.

1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma;Motzer;New England Journal of Medicine,2018

2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Rini;New England Journal of Medicine,2019

3. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma;Choueiri;New England Journal of Medicine,2021

4. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma;Motzer;New England Journal of Medicine,2021

5. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III Check-Mate 214 trial;Albiges;ESMO Open,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing;Translational Oncology;2023-10

2. Application of oncolytic virus in tumor therapy;Journal of Medical Virology;2023-04